Claims for Patent: 9,567,627
✉ Email this page to a colleague
Summary for Patent: 9,567,627
Title: | Method for predicting the response to treatment with an HER2-blocking agent |
Abstract: | The invention relates in particular to an in vitro or ex vivo method for predicting the response of a patient to treatment with at least one HER2-blocking agent, said method including the steps of: i) identifying the nucleotide at the rs3746083 polymorphic site, for at least one allele, in particular the two alleles of the gene coding the tristetraprolin protein, in a biological sample from said patient; and/or ii) determining the concentration of the tristetraprolin protein in a biological sample from said patient, wherein said patient is suffering from HER2-positive cancer. |
Inventor(s): | Pages; Gilles (Monaco, MC) |
Assignee: | UNIVERSITE DE NICE SOPHIA ANTIPOLIS (Nice, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR) |
Application Number: | 14/125,155 |
Patent Claims: | 1. An in vitro or ex vivo method for determining the response of a patient to treatment with trastuzumab and treating a patient determined to be responsive to
treatment with trastuzumab, said method comprising the steps of: i) identifying (a) or (b) at a rs3746083 polymorphic site at position 367 in a nucleotide sequence of SEQ ID NO: 3 coding for a tristetraprolin protein in a biological sample from said
patient: (a) heterozygosity (T/C) or homozygosity (T/T) indicating that said patient is determined to be not responsive to treatment with trastuzumab; (b) homozygosity (C/C) indicating that said patient is determined to be responsive to the treatment
with trastuzumab; ii) determining the level of the tristetraprolin protein in a biological sample from said patient and comparing it with at least one reference value, wherein the level of the tristetraprolin protein in the biological sample is greater
than or equal to a reference value, the patient is predicted to be responsive to the treatment with trastuzumab; and iii) administering trastuzumab to said patient being determined to be responsive to treatment with trastuzumab, wherein said patient is
suffering from HER2-positive breast cancer.
2. An in vitro or ex vivo method of prognosis or diagnosis of HER2-positive breast cancer in a patient and treating a patient determined to have said cancer, comprising: i) identifying (a) or (b) at a rs3746083 polymorphic site at position 367 in a nucleotide sequence of SEQ ID NO: 3 coding for a tristetraprolin protein in a biological sample from said patient; (a) heterozygosity (T/C) or homozygosity (T/T) indicating that said patient is determined to be not responsive to treatment with trastuzumab, (b) homozygosity (C/C) indicating that said patient is determined to be responsive to the treatment with trastuzumab, and ii) administering trastuzumab to said patient being determined to have HER2-positive breast cancer. 3. The method according to claim 2, wherein the cancer is HER2-positive breast cancer with a poor prognosis. |
Details for Patent 9,567,627
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2031-06-10 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2031-06-10 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2031-06-10 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.